Candel Therapeutics Director Renee Gaeta Receives 32,000 Stock Options

Renee Gaeta, a director of Candel Therapeutics, Inc. (CADL), received a grant of 32,000 stock options on June 23, 2026. The options have an exercise price of $9.08 per share and expire on June 23, 2036. The options are subject to time-based vesting, with shares becoming exercisable upon the earlier of June 23, 2027 or the date of the next Annual Meeting of Stockholders. However, vesting will cease if Gaeta resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise. The filing represents a Form 4 disclosure of director equity compensation and was signed by Charles Schoch as attorney-in-fact for Renee Gaeta on June 24, 2026.